首页> 美国卫生研究院文献>other >Determination of the distribution of light optical properties drug concentration and tissue oxygenation in-vivo in human prostate during motexafin lutetium-mediated photodynamic therapy
【2h】

Determination of the distribution of light optical properties drug concentration and tissue oxygenation in-vivo in human prostate during motexafin lutetium-mediated photodynamic therapy

机译:Motexafin et介导的光动力治疗过程中人前列腺中光的分布光学特性药物浓度和体内组织氧合的测定

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

It is desirable to quantify the distribution of the light fluence rate, the optical properties, the drug concentration, and the tissue oxygenation for photodynamic therapy (PDT) of prostate cancer. We have developed an integrated system to determine these quantities before and after PDT treatment using motorized probes. The optical properties (absorption (μa), transport scattering (μs), and effective attenuation (μeff) coefficients) of cancerous human prostate were measured in-vivo using interstitial isotropic detectors. Measurements were made at 732 nm before and after motexafin lutetium (MLu) mediated PDT at different locations along each catheter. The light fluence rate distribution was also measured along the catheters during PDT. Diffuse absorption spectroscopy measurement using a white light source allows extrapolation of the distribution of oxygen saturation (StO2), total blood volume ([Hb]t), and MLu concentration. The distribution of drug concentration was also studied using fluorescence from a single optical fiber, and was found to be in good agreement with the values determined by absorption spectroscopy. This study shows significant inter- and intra-prostatic variations in the tissue optical properties and MLu drug distribution, suggesting that a real-time dosimetry measurement and feedback system for monitoring these values during treatment should be considered in future PDT studies.
机译:对于前列腺癌的光动力疗法(PDT),希望量化光通量率,光学性质,药物浓度和组织氧合的分布。我们已经开发了一个集成系统,可以在使用电动探头进行PDT处理之前和之后确定这些数量。光学特性(吸收(μa),传输散射( < mi>μ s ' )和人类癌性前列腺癌的有效衰减系数(μeff)使用间隙各向同性检测器进行体内测量。 Motexafin et(MLu)介导的PDT沿每个导管的不同位置之前和之后在732 nm处进行测量。在PDT期间,还沿着导管测量了光通量率分布。使用白光源的扩散吸收光谱测量可以推断出氧饱和度(StO2),总血容量([Hb] t)和MLu浓度的分布。还使用来自单根光纤的荧光对药物浓度的分布进行了研究,发现其与吸收光谱法确定的值高度吻合。这项研究表明,前列腺组织内和前列腺组织内光学特性和MLu药物分布的显着变化,表明在未来的PDT研究中应考虑使用实时剂量测定和反馈系统来监测治疗期间的这些值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号